Abstract

PD-25 Disease characteristics and real-world treatment pathways of BRAF V600E-mutant metastatic colorectal cancer patients: Analysis of 120 patients enrolled in the BERING CRC study

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience
...
ESMO open | VOL. 7
, et. al. ...
01 Jun 2022
Adverse Events Associated with Encorafenib Plus Cetuximab in Patients with BRAFV600E-mutant Metastatic Colorectal Cancer: An in-depth Analysis of the BEACON CRC Study
Julien Taieb ... Harpreet Wasan
Clinical colorectal cancer | VOL. 22
Julien Taieb, et. al.Julien Taieb ... Harpreet Wasan
24 Dec 2022
Baseline characteristics of patients enrolled in the BERING CRC study: A European real-world study in BRAF V600E-mutant metastatic colorectal cancer.
Sebastian Stintzing ...
Journal of Clinical Oncology | VOL. 40
Sebastian Stintzing, et. al.Sebastian Stintzing ...
01 Jun 2022
Panitumumab can safely and effectively be substituted for cetuximab in the treatment of BRAF V600Emut metastatic colorectal cancer (mCRC) – A case series
Christian Rausch ... Volker Heinemann
European Journal of Cancer | VOL. 174
Christian Rausch, et. al.Christian Rausch ... Volker Heinemann
12 Aug 2022
View more papers

More From: Annals of oncology : official journal of the European Society for Medical Oncology

Paper Title
Journal
Date
Author
Challenging immune exhaustion in early recurrent triple-negative breast cancer: pitfalls and hopes
P Tarantino ... S M Tolaney
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. 35
P Tarantino, et. al.P Tarantino ... S M Tolaney
01 Jul 2024
ESMO Clinical Practice Guideline interim update on new targeted therapies in the first-line and at relapse of chronic lymphocytic leukaemia
B Eichhorst ... C Buske
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. -
B Eichhorst, et. al.B Eichhorst ... C Buske
01 Jul 2024
Proofreading the way: immune checkpoint inhibitors in polymerase ε/polymerase δ (POLE/POLD1)-altered colorectal cancer
M Cecchini ... R Sundar
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. 35
M Cecchini, et. al.M Cecchini ... R Sundar
01 Jul 2024
Table of Contents
-
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. 35
--
01 Jul 2024
View more papers